These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 7776437

  • 1. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Jul; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 3. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland H.
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of cathepsin D in transitional cell bladder tumours.
    Lipponen PK.
    J Pathol; 1996 Jan; 178(1):59-64. PubMed ID: 8778318
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, Dimopoulos C.
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG.
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [Abstract] [Full Text] [Related]

  • 10. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS, Tsai YS, Chow NH.
    Urol Oncol; 2004 Aug; 22(2):112-8. PubMed ID: 15082007
    [Abstract] [Full Text] [Related]

  • 11. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C.
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [Abstract] [Full Text] [Related]

  • 12. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X, Condom E, Vigués F, Castellsagué X, Figueras A, Muñoz J, Solá J, Soler T, Capellà G, Germà JR.
    Cancer; 2004 May 01; 100(9):1859-67. PubMed ID: 15112266
    [Abstract] [Full Text] [Related]

  • 13. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T, Nesi G, Boddi V, Mazzoli S, Dal Canto M, Bartoletti R.
    Oncol Rep; 2006 Aug 01; 16(2):329-34. PubMed ID: 16820911
    [Abstract] [Full Text] [Related]

  • 14. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
    Leng J, Zhang Y, Yao X, Wen K.
    Zhonghua Wai Ke Za Zhi; 2000 Jan 01; 38(1):40-3. PubMed ID: 11831985
    [Abstract] [Full Text] [Related]

  • 15. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A, Kausch I, Feller AC, Krüger S.
    Oncol Rep; 2005 Oct 01; 14(4):1065-70. PubMed ID: 16142373
    [Abstract] [Full Text] [Related]

  • 16. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT, Sahin A, Altok M, Unlü N, Zorlu F.
    J Urol; 2007 Sep 01; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [Abstract] [Full Text] [Related]

  • 17. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R.
    Cancer; 2002 Sep 01; 95(5):1009-15. PubMed ID: 12209684
    [Abstract] [Full Text] [Related]

  • 18. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
    Saygili U, Koyuncuoglu M, Altunyurt S, Guclu S, Uslu T, Erten O.
    Gynecol Oncol; 2001 Oct 01; 83(1):20-4. PubMed ID: 11585409
    [Abstract] [Full Text] [Related]

  • 19. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N.
    Urol J; 2009 Oct 01; 6(2):101-8. PubMed ID: 19472128
    [Abstract] [Full Text] [Related]

  • 20. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.
    Urology; 2004 Oct 01; 64(4):839-44. PubMed ID: 15491744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.